Biotherapeutics Company Transcenta Holding Secures $100 Million Series B+ Financing

According to PRNewswire.com, Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announced that it has sealed a $100 million series B+ round. CR-CP Life Science Fund ("CR-CP") and Fortune Capital co-led the financing round, participated by new investors including Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, as well as the existing shareholders including Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China, and ARCH Venture Partners. China Renaissance acted as the exclusive financial advisor for this transaction.

Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing. With Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Shanghai, Beijing and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US, Transcenta has established global footprint. Upon the latest financing, the company has raised over $230 million from globally prominent investors. 

Since the merger at the beginning of last year, Transcenta has made significant progresses, for example, it has built a well-rounded team with extensive global industrial experience, assembled a robust pipeline with over 10 innovative molecules in oncology, bone disorders and nephrology, and adopted integrated continuous process and manufacturing in its Hangzhou facility, signed an exclusive license agreement for Greater China with Eli Lilly and Company regarding a portfolio of novel antibodies for bone diseases, including the phase 2-completed Blosozumab for osteoporosis, etc.

CR-CP Life Science Fund is a joint venture set up by China Resources Group and Charoen Pokphand Group. This firm invests in life science companies that develop drugs, cell therapies, medical devices, and smart healthcare technology.

 Established in April 2000, Fortune Capital is one of the earliest market-oriented venture capital firms in China. For the past few years, Fortune Capital focuses its investments on leading companies in four key sectors, including TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.